Journal francais d'ophtalmologie · 2026
Evaluation of the ocular surface in rheumatoid arthritis patients on conventional synthetic disease-modifying antirheumatic drugs.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Demir K, Çakır B, Aksoy N, Kahyaoğlu Z, Gönüllü E
Аннотация
PURPOSE: To evaluate and compare ocular surface findings in rheumatoid arthritis (RA) patients on conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
MATERIALS AND METHODS: The files of adult patients (≥18 years of age) diagnosed with rheumatoid arthritis (RA) according to the 2010 American College of Rheumatology (ACR)-European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis were reviewed retrospectively. RA disease activity was evaluated according to the DAS-28 score, and patients with similar severity of disease were enrolled. Patients who received hydroxychloroquine, methotrexate, and leflunomide treatments were defined as groups 1, 2, and 3, respectively. Ocular surface evaluation, Ocular Surface Disease Index (OSDI) questionnaire, Schirmer 1 test, tear break-up time (TBUT), Oxford scoring according to corneal and conjunctival fluorescein staining (CFS), conjunctival impression cytology (CIC) and the presence of posterior blepharitis were noted and statistically compared between the groups.
RESULTS: The mean age of the 49 RA patients was 57.9±10.2 years; 39 were female, and 10 were male. The mean follow-up period for RA was 12.1±7.8 years. The patients numbered 19, 15, and 14 in groups 1, 2, and 3, respectively. The median OSDI questionnaire scores for the groups were 31.3 (19.2-68.75), 33.4 (19.7-69.7), and 49 (21.1-67.1), respectively (P>0.05). The median Schirmer 1 test was 9mm (2-14mm) in group 1, 8mm (4-20mm) in group 2, and 7mm (5-15mm) in group 3 (P>0.05). Tear film BUT was measured at 7 s (3-10 s), 5.5 s (2-10 s), and 5 s (2-10 s) in the groups, respectively (P>0.05). A statistically significant difference was not found in terms of the Oxford score, which evaluates staining of the ocular surface with fluorescein (P>0.05). According to the Nelson grading of CIC, a statistically insignificant difference was observed between the groups (P>0.05). The presence of posterior blepharitis differed statistically significantly among groups (P=0.003).
CONCLUSION: Although a grade 3 CIC score was observed at a higher rate in the leflunomide group, this difference was not statistically significant. In addition, posterior blepharitis was observed more frequently in patients on methotrexate.
MATERIALS AND METHODS: The files of adult patients (≥18 years of age) diagnosed with rheumatoid arthritis (RA) according to the 2010 American College of Rheumatology (ACR)-European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis were reviewed retrospectively. RA disease activity was evaluated according to the DAS-28 score, and patients with similar severity of disease were enrolled. Patients who received hydroxychloroquine, methotrexate, and leflunomide treatments were defined as groups 1, 2, and 3, respectively. Ocular surface evaluation, Ocular Surface Disease Index (OSDI) questionnaire, Schirmer 1 test, tear break-up time (TBUT), Oxford scoring according to corneal and conjunctival fluorescein staining (CFS), conjunctival impression cytology (CIC) and the presence of posterior blepharitis were noted and statistically compared between the groups.
RESULTS: The mean age of the 49 RA patients was 57.9±10.2 years; 39 were female, and 10 were male. The mean follow-up period for RA was 12.1±7.8 years. The patients numbered 19, 15, and 14 in groups 1, 2, and 3, respectively. The median OSDI questionnaire scores for the groups were 31.3 (19.2-68.75), 33.4 (19.7-69.7), and 49 (21.1-67.1), respectively (P>0.05). The median Schirmer 1 test was 9mm (2-14mm) in group 1, 8mm (4-20mm) in group 2, and 7mm (5-15mm) in group 3 (P>0.05). Tear film BUT was measured at 7 s (3-10 s), 5.5 s (2-10 s), and 5 s (2-10 s) in the groups, respectively (P>0.05). A statistically significant difference was not found in terms of the Oxford score, which evaluates staining of the ocular surface with fluorescein (P>0.05). According to the Nelson grading of CIC, a statistically insignificant difference was observed between the groups (P>0.05). The presence of posterior blepharitis differed statistically significantly among groups (P=0.003).
CONCLUSION: Although a grade 3 CIC score was observed at a higher rate in the leflunomide group, this difference was not statistically significant. In addition, posterior blepharitis was observed more frequently in patients on methotrexate.